Cytosorbents Corp — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
CytoSorbents received notification on September 22, 2026 that it regained compliance with Nasdaq Listing Rule 5550(a)(2) requiring a minimum bid price of $1.00 per share, achieved by maintaining closing bid price ≥$1.00 for 10 consecutive trading sessions ending September 21, 2026. The company remains non-compliant with Nasdaq's Market Value of Listed Securities requirement (≥$35M) and has until December 28, 2026 to satisfy that rule or alternative options. Management reaffirmed focus on CytoSorb sales, operating cash flow breakeven in H2 2026, DrugSorb-ATR FDA approval, and HemoDefend-BGA value.
Why this rating
Compliance restoration is procedurally positive but addresses only one of two Nasdaq rules; material delisting risk remains on market cap ($60.6M vs $35M requirement) before Dec 28 deadline. Moderate concern.
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.